Methods for allogenic hematopoietic stem cell transplantation
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsEverett Hurteau Meyer, Robert S. Negrin
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsEverett Hurteau Meyer, Robert S. Negrin
Estimating the term…
The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.
A pharmaceutical dosing system for hematopoietic cell transplantation to a human subject in need, wherein the pharmaceutical dosing system comprises:
Dependencies are inferred from the claim text.